With a platform drug and off label potential nibbling away from indication based profits (unless partnership is country-based), don’t rule out a buy-out in my opinion. The difficulty of unraveling indication-specific revenue based on an article I read covering this topic, makes the odds of a buyout much higher. The CC went above and beyond to explain their dedication and all hands on deck priority to get passed the clinical hold. If a buyer were in the wings they may want that roadblock removed before a deal. You can make the same argument for partnership but it is a more compelling case if we are headed to buyout. Either way it sounds like the right priority and up there with BLA but I see them linked or more accurately perhaps the later is a dependency.

“Is the data reformatted yet?!” Can’t happen soon enough for me and I suspect all of us here.